Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Darolutamide + ADT in High-Risk Prostate Cancer
NCT06575257Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by Xijing Hospital. Primary endpoints: Pathologic Complete Response Rate at 12 weeks and Proportion of Subjects With Minimal Residual Disease at 12 weeks. Started May 2024; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06575257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575257.